SciQuest (NASDAQ:SQI) said it is starting an underwritten public offering of 3,000,000 shares of common stock pursuant to an effective shelf registration statement. The last reported sale price of the company’s common stock on March 21, 2014 was $30.41 per share. The company also intends to grant the underwriters an option to purchase up to 450,000 additional shares of common stock. The company expects to … Continue reading SciQuest Dips 1% on 3 Million Share Offering

Dover (DOV) was started with a Neutral rating at Goldman Sachs, and shares nosed down less than 1%. Goldman placed an $88 price target on the shares of the diversified manufacturer. In afternoon trade, DOV was off 0.33% to $81.20. Insulet (PODD) was started with a buy rating at Sterne Agee. Shares fell less than 1%. vSterne Agee set a $61 price target on the medical device … Continue reading Stocks Moving On Analyst Actions

Celgene Corp (NASDAQ:CELG) was unchanged in Friday’s after-market and the biotech company confirmed the U.S. Food and Drug Administration has approved the company’s psoriatic arthritis treatment, the first of its kind in this country. The drug will be marketed commercially as Otezla. According to the company, the drug works differently than other approved therapies through the intracellular inhibition of phosphodiesterase 4, an enzyme that plays … Continue reading After Hours Movers: NASDAQ:CELG, NASDAQ:LAMR, NYSEMKT:FRD

NovaBay Pharmaceuticals (NYSEMKT:NBY) is lower in late trading after the clinical-stage biopharmaceutical company said late Wednesday that it intends to offer shares of its common stock and warrants in an underwritten public offering. Shares are down 8.73% at $1.15, with a 52-week range of $0.76 – $2.03. The company intends to use the net proceeds from this offering for working capital and general corporate purposes, … Continue reading NovaBay Pharmaceuticals Tumbles 9% in After Hours; Guess (GES) Down as Well